Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGB-400 for facial redness
NCT04508660Phase 1Completed
- Sponsor
- CAGE Bio
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of choline geranate in rosacea, sponsored by CAGE Bio. Primary endpoint: Investigator's Global Assessment of Redness at 4 weeks. Started Oct 2018; status: completed.
02
Drugs
choline geranate
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT04508660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508660.